Source: FE Investegate

DalCor Pharmaceuticals: DalCor Pharmaceuticals : DalCor announces dal-GenE trial to continue as planned following interim futility analysis

12:00 PM: DalCor announces dal-GenE trial to continue as planned following interim futility analysis

Read full article »
DalCor Pharmaceuticals's Competitors | DalCor Pharmaceuticals's News | DalCor Pharmaceuticals's Financials
Stay up-to-date with the latest news on DalCor
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Fouzia Laghrissi-Thode's photo - CEO of DalCor

CEO

Fouzia Laghrissi-Thode

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on DalCor